EUVIMEDEUVIMED entdecken
Crossref

Antineovascular Effects of Coenzyme Q10 and Vitamin E Combination in Corneal Neovascularization: A Pilot Study

Armağan Özgür iD, Mehmet Cüneyt Özmen, Duygu Yalınbaş Yeter, Mehmet Arda İnan

Journal of Ocular Pharmacology and Therapeutics · 2025

DOI: 10.1089/jop.2025.0068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2025. Verfasst von Armağan Özgür und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Ankara Bilkent City Hospital, Ankara, Turkiye. Hauptthemen laut MEDLINE: Ubiquinone, Vitamin E, Corneal Neovascularization. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate and compare the effects of subconjunctival injection of coenzyme Q10 (CoQ10) and vitamin E (Vit E) ophthalmic solution (Coqun®) with subconjunctival bevacizumab in a suture-induced corneal neovascularization (CoNV) rabbit model. Materials and Methods: CoNV was induced in the right eyes of 24 New Zealand rabbits using a 7.0 silk suture. One week after suturing, the rabbits were randomly divided into four groups and treated with a subconjunctival injection of either 0.1 mL balanced salt solution (control), bevacizumab (2.5 mg/0.1 mL), or two different doses of Coqun [(2 mg CoQ10 + 10 mg Vit E/0.2 mL) and (4 mg CoQ10 + 20 mg Vit E/0.4 mL)]. Photographs were taken on day 7 (pre-injection) and day 14 (7 days post-injection). On day 14, the regression area of CoNV was measured for analysis, and enucleation was performed for histopathological evaluation.

Results

The CoNV areas after treatment were smaller in all three treatment groups compared with the control group (p < 0.01). The mean percentage of CoNV regression was highest in the bevacizumab group (87.8% ± 3.2%), followed by the Coqun groups (69.5% ± 5.9% in the 0.2 mL dose, and 67.1% ± 9.3% in the 0.4 mL dose) No significant difference was observed between the two different doses of Coqun (p = 0.99).

Conclusions

Subconjunctival administration of Coqun ophthalmic solution may offer a beneficial adjunct for the treatment of CoNV. Although it is not less effective than bevacizumab, its neuroprotective properties suggest potential value in cases where CoNV and glaucoma coexist. Further clinical studies are warranted to confirm these findings and to better define its therapeutic role.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UbiquinoneVitamin ECorneal NeovascularizationAnimalsRabbitsPilot ProjectsBevacizumabAngiogenesis InhibitorsDisease Models, AnimalOphthalmic SolutionsDrug Therapy, CombinationMale

Stichwörter der Autor:innen

animal modelbevacizumabcoenzyme Q10corneal neovascularizationvitamin E

Substanzen

Ubiquinonecoenzyme Q10Vitamin EBevacizumabAngiogenesis InhibitorsOphthalmic Solutions

Autor:innen und Institutionen

  • Department of Ophthalmology, Ankara Bilkent City Hospital, Ankara, Turkiye.
  • Department of Ophthalmology, Gazi University Medical School, Ankara, Turkiye.
  • Department of Ophthalmology, Cumhuriyet University Medical School, Sivas, Turkiye.
  • Department of Pathology, Gazi University Medical School, Ankara, Turkiye.

ORCID-Profile: Armağan Özgür

Zitieren

APA

Özgür, A., Özmen, M. C., Yalınbaş Yeter, D., & İnan, M. A. (2025). Antineovascular Effects of Coenzyme Q10 and Vitamin E Combination in Corneal Neovascularization: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2025.0068

Vancouver

Özgür A, Özmen MC, Yalınbaş Yeter D, İnan MA. Antineovascular Effects of Coenzyme Q10 and Vitamin E Combination in Corneal Neovascularization: A Pilot Study. Journal of Ocular Pharmacology and Therapeutics. 2025. doi:10.1089/jop.2025.0068

BibTeX
@article{zgr2025,
  author = {Özgür, Armağan and Özmen, Mehmet Cüneyt and Yalınbaş Yeter, Duygu and İnan, Mehmet Arda},
  title = {Antineovascular Effects of Coenzyme Q10 and Vitamin E Combination in Corneal Neovascularization: A Pilot Study},
  journal = {Journal of Ocular Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.1089/jop.2025.0068}
}
Kostenlos starten →